Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.

2025-07-29 19:10:01

weight loss drug Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Beijing, the "capital of open source", accelerates the construction of domestic open source big models and achieves another breakthrough
                            2025-07-25

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    PICO and Blender Foundation enter into partnership
                            2025-07-23

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    Jida Zhengyuan was selected into Huawei Digital Government High-Quality Service Industry Alliance
                            2025-07-22